血清HE4和SCCAg与子宫内膜癌生物学行为的关系

doi:10.3969/j.issn.1673-8640.2014.05.013

检验医学 ›› 2014, Vol. 29 ›› Issue (5): 488-491.DOI: 10.3969/j.issn.1673-8640.2014.05.013

血清HE4和SCCAg与子宫内膜癌生物学行为的关系

劳明, 吴芸, 朱波, 黄文成, 黄玲莎, 王英, 李美琴, 朱春燕, 刘金凤

广西医科大学附属肿瘤医院检验科, 广西南宁 530021

收稿日期:2013-07-03 出版日期:2014-05-30 发布日期:2014-05-27
作者简介:劳明, 男, 1968年生, 学士, 主任技师, 主要从事肿瘤实验诊断的基础研究。
基金资助:
广西壮族自治区卫生厅计划科研课题资助项目(Z2013413)

Serum levels of HE4 and SCCAg and their relationships with biological behavior of endometrial carcinoma

LAO Ming, WU Yun, ZHU Bo, HUANG Wencheng, HUANG Lingsha, WANG Ying, LI Meiqin, ZHU Chunyan, LIU Jinfeng.

Department of Clinical Laboratory, Tumor Hospital of Guangxi Medical University, Guangxi Nanning 530021, China

Received:2013-07-03 Online:2014-05-30 Published:2014-05-27

摘要/Abstract

摘要： 目的探讨人附睾分泌蛋白4(HE4) 和鳞状细胞癌抗原(SCCAg)在子宫内膜癌的表达及两者与子宫内膜癌生物学行为的关系。方法利用酶联免疫吸附试验检测85例子宫内膜癌患者、30例子宫内膜非典型增生患者及30名健康女性(对照组)血清HE4和SCCAg含量, 并对比分析两者对子宫内膜癌的临床价值。结果子宫内膜癌组血清HE4和SCCAg水平分别为(199.6±31.2)pmol/L、0.98(0.15~4.85)μg/L, 明显高于子宫内膜非典型增生组[(91.6±16.8)pmol/L、0.18(0.02~1.41)μg/L, P均<0.05]和对照组[(82.5±9.7)pmol/L、0.13(0.03~1.32)μg/L, P均<0.05]; HE4和SCCAg对子宫内膜癌诊断的敏感性分别为63.5%、14.1%, 特异性为96.7%、100.0%;血清HE4和SCCAg水平及阳性率均随临床分期升高逐渐上升, 两者在子宫内膜癌晚期的阳性率(HE4:Ⅲ期90.0%、Ⅳ期100.0%;SCCAg:Ⅲ期30.0%、Ⅳ期25.0%)明显高于早期(Ⅰ期分别为61.1%和5.6%, P均<0.05);在不同的临床病理因素中, 非子宫内膜样腺癌HE4阳性率达92.0%, 明显高于子宫内膜样腺癌(51.7, P<0.05), HE4在子宫内膜癌的表达与肿瘤大小、病理类型、肿瘤侵润肌层深度及肿瘤转移均有关(P均<0.05);而SCCAg在子宫内膜癌的表达仅与肿瘤转移有关(P<0.01)。结论血清HE4检测对子宫内膜癌的早期诊断及鉴别诊断有一定的临床应用价值, 可作为子宫内膜癌病程监测的可靠指标。而SCCAg单独作为子宫内膜癌诊断指标尚无太大意义, 仅在病程监测及判断肿瘤转移上有一定价值。

关键词: 人附睾分泌蛋白4, 鳞状细胞癌抗原, 子宫内膜癌, 恶性肿瘤

Abstract: Objective To investigate human epididymal secretory protein 4 (HE4) and squamous cell carcinoma antigen (SCCAg) levels in endometrial carcinoma and their relationships with biological behavior of endometrial carcinoma. Methods Serum levels of HE4 and SCCAg were detected by enzyme-linked immunosorbent assay in 85 patients with endometrial carcinoma, 30 patients with endometrial atypical hyperplasia and 30 healthy women (control group). The clinical signicance of HE4 and SCCAg were analyzed comparatively. Results Serum levels of HE4 and SCCAg were (199.6 ± 31.2) pmol/L and 0.98(0.15-4.85) μg/L in patients with endometrial carcinoma, which were higher than those in patients with endometrial atypical hyperplasia [(91.6 ± 16.8) pmol/L and 0.18(0.02-1.41) μg/L, P<0.05] and control group [(82.5 ± 9.7) pmol/L and 0.13(0.03-1.32) μg/L, P<0.05]. The diagnosis sensitivities of HE4 and SCCAg for the diagnosis of endometrial carcinoma were 63.5% and 14.1%, and the specificities were 96.7% and 100.0%. Serum HE4 and SCCAg levels and the positive rates had increasing trend with stage rising, and the positive rates in advanced stages of endometrial carcinoma (HE4: 90.0% for stage Ⅲ and 100.0% for stage Ⅳ, SCCAg: 30.0% for stage Ⅲ and 25.0% for stage Ⅳ), which were higher than those in early stage(61.1% and 5.6% for stage Ⅰ, P<0.05). For different clinical pathological factors, the positive rate of HE4 in non-endometrial adenocarcinoma was up to 92.0%, which was higher than that in endometrial adenocarcinoma (51.7%, P<0.05). HE4 expression in endometrial carcinoma had the relationship with tumor size, pathological type, depth of tumor invasion and tumor metastasis (P<0.05), and SCCAg expression in endometrial carcinoma had the relationship with tumor metastasis only (P<0.01). Conclusions Serum HE4 has clinical early diagnosis and identification significance for endometrial carcinoma, and it can be used as an indicator for monitoring endometrial carcinoma. However, SCCAg had a little diagnosis significance for the diagnosis of endometrial carcinoma. It only has a certain significance in the course of monitoring and tumor metastasis identification.

Key words: Human epididymal secretory protein 4, Squamous cell carcinoma antigen, Endometrial carcinoma, Malignant tumor

中图分类号:

R446.62

劳明, 吴芸, 朱波, 黄文成, 黄玲莎, 王英, 李美琴, 朱春燕, 刘金凤. 血清HE4和SCCAg与子宫内膜癌生物学行为的关系[J]. 检验医学, 2014, 29(5): 488-491.

LAO Ming, WU Yun, ZHU Bo, HUANG Wencheng, HUANG Lingsha, WANG Ying, LI Meiqin, ZHU Chunyan, LIU Jinfeng.. Serum levels of HE4 and SCCAg and their relationships with biological behavior of endometrial carcinoma[J]. , 2014, 29(5): 488-491.

参考文献

[1] 刘颖, 韩秋峪, 刘慧, 等.子宫内膜癌中C-erbB-2、Ki-67表达及血清CA125水平与临床病理特征的关系[J].放射免疫学杂志, 2010, 23(4):419-421.
[2] 丛培珊, 孙桂荣, 张娜娜, 等.人附睾蛋白4对子宫内膜癌和卵巢癌早期辅助诊断价值的评估[J].检验医学, 2011, 26(7): 447-451.
[3] Hellstrm I, Raycraft J, Hayden-Ledbetter M, et al.The HFA(WFDC2)protein is a biomarker for ovarian carcinoma[J].Cancer Res, 2003, 63(13):3695-3700.
[4] Galgano MT, Hampton GM, Frierson HF Jr.Comprehensive analysis of HE4 expression in normal and malignant human tissues[J].Mod Pathol, 2006, 19(6):847-853.
[5] Fejzo MS, Dering J, Ginther C, et al. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target[J].Genes Chromosomes Cancer, 2008, 47(10):873-883.
[6] Anderson GL, Mclntosh M, Wu L, et al.Assessing lead time of selected ovarian cancer biomarker:a nested case-control study[J].J Natl Cancer Inst, 2010, 102(1):26-38.
[7] Moore RG, Brown AK, Miller MC, et al.Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus[J].Gynecol Oncol, 2008, 110(2):196-201.
[8] 马荣, 耿晓星, 唐丽萍, 等. 人附睾分泌蛋白4检测对子宫内膜癌的诊断及预后的意义[J].临床肿瘤学杂志, 2011, 16(9):790-793.
[9] 李卫鹏, 张蕾蕾.鳞状细胞癌抗原研究进展[J].放射免疫学杂志, 2010, 23(1):34-37.
[10] 吕秋波, 申桂华, 伍凤莉, 等. 血清CA125、CA19-9、CEA及SCC水平在子宫内膜癌患者中的诊断意义[J].中国肿瘤临床, 2002, 29(9):638-640.
[11] Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4(HE4)is a secreted glycolprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Res, 2005, 65(6):2162-2169.

[1]	卫明珠, 潘继文, 罗锐, 陈俊辉. 凝血4项和肿瘤标志物对乙型肝炎相关肝癌的辅助诊断价值[J]. 检验医学, 2023, 38(9): 901-904.
[2]	郭洁, 李海霞, 李小云. 术前外周血红细胞分布宽度/血小板计数比值与子宫内膜癌患者预后的相关性[J]. 检验医学, 2023, 38(7): 675-679.
[3]	袁爽, 冯磊, 郭小芬, 付小玲, 许静, 刘弘扬. 子宫内膜癌组织miR-433的表达及其与化疗敏感性的关系[J]. 检验医学, 2023, 38(4): 337-341.
[4]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[5]	吴亚婷, 李卓林, 雷艳, 贾如雪, 张胜行, 王水良. 尿液中miRNA作为常见恶性肿瘤生物标志物研究进展[J]. 检验医学, 2023, 38(1): 94-99.
[6]	刘训涛, 王霞, 赵飞, 郭迪媛, 张斌. 异常表达CD13的B细胞恶性肿瘤患者形态学和流式细胞术检测结果分析[J]. 检验医学, 2022, 37(5): 499-501.
[7]	邵华卿, 陈文欣, 胡晓波. PLR、NLR联合检测在消化道恶性肿瘤中的临床意义[J]. 检验医学, 2022, 37(4): 374-376.
[8]	袁霜, 王丽华. 基于内源性竞争性网络的Ⅰ型、Ⅱ型子宫内膜癌关键长非编码RNA和微小RNA分析[J]. 检验医学, 2021, 36(5): 535-543.
[9]	张萍, 杨波, 蔡小玲, 熊婉媛, 魏绪磐, 铁宝霞. 外泌体微小RNA研究进展及诊断价值[J]. 检验医学, 2019, 34(12): 1139-1144.
[10]	马丽娜, 孙笑, 王丽华. 1型胰岛素样生长因子受体和表皮生长因子受体在子宫内膜癌中的临床价值[J]. 检验医学, 2019, 34(10): 918-922.
[11]	杨滇宇, 权文强, 孙祖俊, 李冬. RDW在恶性肿瘤诊疗中的最新应用[J]. 检验医学, 2018, 33(9): 844-549.
[12]	陈文欣, 李强, 薛赢俊, 邵华卿, 李贞, 陆文倩, 胡晓波. 恶性肿瘤患者凝血 - 纤溶系统标志物检测及其临床意义[J]. 检验医学, 2018, 33(8): 722-726.
[13]	陶朝欣, 邢江涛, 李建英, 许丽亚, 张玉娜, 朱芸. 儿童卵巢恶性肿瘤并发骨髓增生异常综合征1例报道[J]. 检验医学, 2018, 33(8): 772-774.
[14]	刘秋颖, 陈锋, 崔婵娟, 黄声凯, 崔巍. 恶性肿瘤患者出现单纯凝血酶时间明显延长的原因探讨[J]. 检验医学, 2018, 33(10): 967-968.
[15]	刘风华, 王李洁, 周运恒, 李戬, 胡琼. 探索15项生化指标联合检测对肝脏恶性肿瘤首次治疗后的应用价值[J]. 检验医学, 2017, 32(5): 353-360.

血清HE4和SCCAg与子宫内膜癌生物学行为的关系

Serum levels of HE4 and SCCAg and their relationships with biological behavior of endometrial carcinoma

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics